Johnson & Johnson (J&J) MedTech’s Shockwave Medical has launched the E⁸ peripheral intravascular (IVL) catheter in the US for patients living with certain types of peripheral artery disease (PAD).

Shockwave Medical, Inc. SWAV, along with Genesis MedTech Group, received approval from China’s National Medical Products Administration for Intravascular Lithotripsy (“IVL”). The clearance paves the ...

SANTA CLARA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of ...

Shockwave C2+ Catheter Expands Utility of IVL in Calcified Coronary Arteries Shockwave C2+ is commercially available for the treatment of de novo coronary artery disease in Europe and select other ...

Shockwave Medical, Inc. SWAV recently announced the full U.S. commercial availability of the Shockwave L6 Peripheral Intravascular Lithotripsy (IVL) Catheter. This follows the receipt of the FDA’s ...

A detailed agenda for all Shockwave Medical symposia and featured presentations can be found here. While under clinical investigation in the COSIRA-II trial (U.S. and Canada), the Reducer is CE-marked ...

Physicians have a number of tools to treat coronary artery disease, the most common type of heart disease in the United States. But one breakthrough technology being offered at Catholic Medical Center ...

Novel Intravascular Lithotripsy (IVL) catheter demonstrates ability to modify calcium safely, enabling treatment and crossing of tightly-stenosed lower limb lesions Technology has received U.S. FDA ...

Shockwave Medical, Inc. SWAV recently commercially launched the Shockwave M5+ peripheral intravascular lithotripsy (“IVL”) catheter. Commercial availability of the product in Europe and the United ...

Shockwave Medical is moving to get its Intravascular Lithotripsy (IVL) technology approved in Japan. The Santa Clara-based company said it has initiated the DISRUPT CAD IV study of IVL in heavily ...